CA3003294C - Recepteur epha4 modifie et utilisations connexes - Google Patents

Recepteur epha4 modifie et utilisations connexes

Info

Publication number
CA3003294C
CA3003294C CA3003294A CA3003294A CA3003294C CA 3003294 C CA3003294 C CA 3003294C CA 3003294 A CA3003294 A CA 3003294A CA 3003294 A CA3003294 A CA 3003294A CA 3003294 C CA3003294 C CA 3003294C
Authority
CA
Canada
Prior art keywords
epha4
amino acid
seq
acid sequence
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3003294A
Other languages
English (en)
Other versions
CA3003294A1 (fr
Inventor
Perry Bartlett
Andrew Boyd
Mike GEROMETTA
Leanne COOPER
Original Assignee
University of Queensland UQ
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ, Queensland Institute of Medical Research QIMR filed Critical University of Queensland UQ
Priority claimed from PCT/AU2016/051010 external-priority patent/WO2017070738A1/fr
Publication of CA3003294A1 publication Critical patent/CA3003294A1/fr
Application granted granted Critical
Publication of CA3003294C publication Critical patent/CA3003294C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente demande concerne généralement le traitement de maladies et de conditions exacerbées par le signalement par des kinases de récepteur dans la famille de l’hépatome produisant de l’érythropoïétine (Eph) et des agents utiles dans un tel traitement.
CA3003294A 2015-10-27 2016-10-27 Recepteur epha4 modifie et utilisations connexes Active CA3003294C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015904387A AU2015904387A0 (en) 2015-10-27 A method of treatment and agents useful for same
AU2015904387 2015-10-27
PCT/AU2016/051010 WO2017070738A1 (fr) 2015-10-27 2016-10-27 Procédé de traitement et agents utiles audit procédé

Publications (2)

Publication Number Publication Date
CA3003294A1 CA3003294A1 (fr) 2017-05-04
CA3003294C true CA3003294C (fr) 2026-02-17

Family

ID=

Similar Documents

Publication Publication Date Title
US10287336B2 (en) Feline erythropoietin receptor agonists
AU2016345063B2 (en) A method of treatment and agents useful for same
CZ386392A3 (en) Alpha interferon
US20220280619A1 (en) Dna vaccine against amyloid-beta and tau
EP3894434A1 (fr) Analogues de l'érythropoïétine à usage vétérinaire
CA3003294C (fr) Recepteur epha4 modifie et utilisations connexes
JP6120133B2 (ja) 人工ポリクローナル免疫グロブリン組成物
JP2001509391A (ja) ウシｉｆ１ａｔｐアーゼインヒビタータンパク質由来のコイルドコイル構造を含む融合タンパク質
KR102485892B1 (ko) 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
KR102201154B1 (ko) 폴리글루타메이트-TAT-Cre 융합 단백질의 제조방법
US20220259290A1 (en) Innovative production technique for antibody-enzyme
CN116139278B (zh) 一种tim-3棕榈酰化修饰及靶向多肽在肿瘤免疫治疗中的应用
US20250250320A1 (en) Thrombopoietin receptor fragments and uses thereof
JP7284447B2 (ja) 融合タンパク質、該融合タンパク質をコードする核酸、組み換えベクター、形質転換された宿主細胞、エキソソームの機能調節剤、及びエキソソーム
CN117642422A (zh) 用于降低抗体-脂肪酶结合的结构
AU2023376942A1 (en) Methods of making fusion polypeptides
KR20240087579A (ko) 항-타우 항체 및 펩티드를 포함하는 융합체와 그의 용도
AU2024241785A1 (en) Ides variant proteins and methods of using the same
JPWO2009017255A1 (ja) 変異導入ＭｙＤ８８蛋白によるＴｏｌｌ様受容体／インターロイキン１８シグナルの特異的制御法
HK1165461A (en) In tumours differentially expressed gene products and use of the same
HK1165480A1 (zh) 肿瘤内差异表达的基因产物及其应用
HK1165467A (en) In tumours differentially expressed gene products and use of the same
HK1165468A (en) In tumours differentially expressed gene products and use of the same